.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Fish and Richardson
Accenture
Farmers Insurance
McKinsey
Cipla
UBS
Mallinckrodt
Cerilliant
Chubb

Generated: June 25, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,458,924

« Back to Dashboard

Which drugs does patent 6,458,924 protect, and when does it expire?


Patent 6,458,924 protects SAXENDA, VICTOZA, and XULTOPHY 100/3.6, and is included in three NDAs. There has been one Paragraph IV challenge on Victoza.

This patent has eighty-eight patent family members in twenty-three countries.

Summary for Patent: 6,458,924

Title: Derivatives of GLP-1 analogs
Abstract:The present invention relates to a pharmaceutical composition comprising a GLP-1 derivative having a lipophilic substituent; and a surfactant.
Inventor(s): Knudsen; Liselotte Bjerre (Valby, DK), Huusfeldt; Per Olaf (K.o slashed.benhavn K, DK), Nielsen; Per Franklin (V.ae butted.rl.o slashed.se, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:09/398,111
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novo Nordisk Inc
SAXENDA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes6,458,924► SubscribeYY METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
Novo Nordisk Inc
VICTOZA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS022341-001Jan 25, 2010RXYesYes6,458,924► SubscribeYY A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
Novo Nordisk Inc
XULTOPHY 100/3.6
insulin degludec; liraglutide
SOLUTION;SUBCUTANEOUS208583-001Nov 21, 2016RXYesYes6,458,924► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,458,924

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark0931/96Aug 30, 1996
Denmark1259/96Nov 08, 1996
Denmark1470/96Dec 20, 1996
Denmark0263/98Feb 27, 1998
Denmark0264/98Feb 27, 1998

Non-Orange Book Patents for Patent: 6,458,924

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,235,627Derivatives of GLP-1 analogs► Subscribe
6,268,343 Derivatives of GLP-1 analogs► Subscribe
8,097,698Derivatives of GLP-1 analogs► Subscribe
7,226,990Extendin derivatives► Subscribe
6,384,016 Stabilized aqueous peptide solutions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,458,924

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Israel189136► Subscribe
Japan2000500505► Subscribe
Japan3149958► Subscribe
Japan2003526599► Subscribe
Japan4072319► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Farmers Insurance
Argus Health
US Army
Julphar
Cipla
Novartis
Cantor Fitzgerald
Harvard Business School
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot